ADAR1 Capital Management, LLC
In its 13F for Q4 2024 (holdings as of December 31, 2024, filed February 13, 2025), ADAR1 Capital Management, LLC reported 185 stock positions worth $469.3 million. Its top holding was Roivant Sciences (ROIV) at 8.8% of the portfolio, followed by Protagonist Therapeutics (PTGX, 8.4%) and Alpha Architect 1-3 MNTH Box (BOXX, 7.6%). Compared with Q3 2024, it opened 42 new positions, sold out of 101, added to 54 and reduced 66. The biggest buy was Zai Lab Ltd.-ADR (ZLAB, shares +96%) and the biggest sale Royalty Pharma Class A (RPRX, shares −95%).
- Most Recent 13F
- Q2 2026
- Location
- AUSTIN, TX
- CIK
- 0001940272
- Portfolio Value
- $469.3M (Q4 2024)
- SEC Filing
- 0001940272-25-000001 ↗ filed Feb 13, 2025
Holdings Value
Holdings 185 stocks · $469.3M
| ROIV Roivant Sciences Ltd. | 8.84% | 3,508,694 | $41.5M | Add +16.0% |
| PTGX Protagonist Therapeutics Inc. | 8.39% | 1,020,333 | $39.4M | Add +4.0% |
| BOXX Alpha Architect 1-3 MNTH Box | 7.65% | 325,450 | $35.9M | Add +0.6% |
| ZLAB Zai Lab Ltd.-ADR | 5.84% | 1,045,837 | $27.4M | Add +96.4% |
| IMVT Immunovant Inc. | 4.16% | 787,478 | $19.5M | Reduce -30.4% |
| CYTK Cytokinetics Inc. | 4.15% | 414,209 | $19.5M | Reduce -54.5% |
| BBIO Bridgebio Pharma Inc. | 3.97% | 678,857 | $18.6M | Reduce -53.1% |
| IKT Inhibikase Therapeutics Inc. | 3.53% | 5,103,005 | $16.6M | New |
| BIL SS SPDR BB 1-3M T-Bill ETF | 2.57% | 131,786 | $12.0M | Add +504.9% |
| ABVX Abivax SA-ADR | 2.36% | 1,513,393 | $11.1M | Add +190.1% |
| MLYS Mineralys Therapeutics Inc. | 2.21% | 841,541 | $10.4M | Add +15.4% |
| ASND Ascendis Pharma A/S | 2.09% | 71,402 | $9.8M | Reduce -55.8% |
| FRNM Freenome Inc. filed as PERCEPTIVE CAP SOLUTIONS COR | 1.63% | 750,000 | $7.6M | No change |
| RVMD Revolution Medicines Inc. | 1.58% | 170,000 | $7.4M | Add +283.3% |
| RZLT Rezolute Inc. | 1.42% | 1,359,208 | $6.7M | Reduce -13.5% |
| EDR Endeavor Group Hold Class A | 1.40% | 210,729 | $6.6M | Add +71.6% |
| CGON CG Oncology Inc. | 1.32% | 215,750 | $6.2M | Add +50.8% |
| AVR Anteris Technologies Global | 1.25% | 1,052,968 | $5.9M | New |
| AAM Aa Mission Acquisition Cor-A | 1.21% | 560,199 | $5.7M | Reduce -44.5% |
| XNCR Xencor Inc. | 1.15% | 234,607 | $5.4M | Reduce -31.4% |
| ZURA Zura Bio Ltd. | 1.11% | 2,077,251 | $5.2M | Reduce -44.9% |
| ABUS Arbutus Biopharma Corp. | 1.08% | 1,554,802 | $5.1M | Reduce -25.6% |
| OACCU Oaktree Acquisition III Life | 1.08% | 500,000 | $5.1M | New |
| SRPT Sarepta Therapeutics Inc. | 1.04% | 40,002 | $4.9M | Add +463.4% |
| SNY Sanofi-ADR | 1.02% | 99,600 | $4.8M | New |
| BBOT Bridgebio Oncology Therapeut filed as HELIX ACQUISITION CORP II | 0.90% | 404,138 | $4.2M | No change |
| ETNB 89BIO Inc. | 0.86% | 515,138 | $4.0M | Add +7752.7% |
| MRUS Merus NV | 0.73% | 81,460 | $3.4M | Reduce -46.9% |
| KNSA Kiniksa Pharmaceuticals Inte | 0.70% | 166,406 | $3.3M | Reduce -61.9% |
| ALDX Aldeyra Therapeutics Inc. | 0.69% | 647,960 | $3.2M | Add +114.4% |
| TEVA Teva Pharmaceutical-SP ADR | 0.69% | 146,671 | $3.2M | Add +35.6% |
| SVRA Savara Inc. | 0.65% | 988,468 | $3.0M | Add +33.1% |
| GRCE Grace Therapeutics Inc. | 0.62% | 773,635 | $2.9M | Reduce -19.4% |
| MNPR Monopar Therapeutics Inc. | 0.61% | 130,037 | $2.9M | New |
| CRNX Crinetics Pharmaceuticals Inc. | 0.58% | 53,125 | $2.7M | Reduce -39.9% |
| TECX Tectonic Therapeutic Inc. | 0.58% | 58,708 | $2.7M | Reduce -53.8% |
| RCKT Rocket Pharmaceuticals Inc. | 0.57% | 211,400 | $2.7M | Add +4816.3% |
| CNTA Centessa Pharmaceuticals Ltd. | 0.55% | 154,027 | $2.6M | Add +561.0% |
| AEROVATE THERAPEUTICS INC | 0.52% | 928,016 | $2.5M | Add +720.7% |
| KRRO Korro Bio Inc. | 0.47% | 57,978 | $2.2M | Add +17.2% |
| PTCT PTC Therapeutics Inc. | 0.46% | 48,023 | $2.2M | Add +140.1% |
| ASPCU A Spac III Acquisition Corp. | 0.46% | 215,000 | $2.2M | New |
| XENE Xenon Pharmaceuticals Inc. | 0.42% | 50,547 | $2.0M | Add +81.2% |
| APGE Apogee Therapeutics Inc. | 0.40% | 41,274 | $1.9M | Reduce -27.8% |
| RAPT THERAPEUTICS INC | 0.40% | 1,174,313 | $1.9M | Add +15557.5% |
| DCTH Delcath Systems Inc. | 0.38% | 149,385 | $1.8M | Add +381.1% |
| PLRX Pliant Therapeutics Inc. | 0.38% | 134,798 | $1.8M | Reduce -45.2% |
| PVLA Palvella Therapeutics Inc. | 0.37% | 144,641 | $1.7M | New |
| RYTM Rhythm Pharmaceuticals Inc. | 0.37% | 30,941 | $1.7M | New |
| JANX Janux Therapeutics Inc. | 0.36% | 31,509 | $1.7M | Add +142.4% |
| AXSM Axsome Therapeutics Inc. | 0.35% | 19,661 | $1.7M | Add +3176.8% |
| SLNO Soleno Therapeutics Inc. | 0.35% | 36,830 | $1.7M | Add +268.3% |
| KALA Kala Bio Inc. | 0.33% | 220,373 | $1.5M | Reduce -28.0% |
| ARES ACQUISITION CORP II | 0.33% | 138,966 | $1.5M | No change |
| INSM Insmed Inc. | 0.32% | 21,974 | $1.5M | Add +504.7% |
| CDMO Avid Bioservices Inc. | 0.32% | 120,000 | $1.5M | New |
| SLRN Acelyrin Inc. | 0.30% | 444,967 | $1.4M | Add +731.7% |
| VRNA Verona Pharma Ltd. | 0.29% | 29,100 | $1.4M | Add +191.0% |
| RGNX Regenxbio Inc. | 0.28% | 170,129 | $1.3M | Reduce -70.1% |
| PSTX Poseida Therapeutics Inc. | 0.27% | 134,109 | $1.3M | New |
| RPRX Royalty Pharma PLC Class A | 0.27% | 49,963 | $1.3M | Reduce -95.4% |
| CTNM Contineum Therapeutics Inc. Class A | 0.26% | 82,234 | $1.2M | Add +817.1% |
| ACOG Alpha Cognition Inc. | 0.26% | 204,348 | $1.2M | New |
| GERN Geron Corp. | 0.25% | 337,676 | $1.2M | Reduce -39.4% |
| LXEO Lexeo Therapeutics Inc. | 0.24% | 169,505 | $1.1M | Add +196.5% |
| LLY Eli Lilly & Co. | 0.22% | 1,350 | $1.0M | Add +17.4% |
| IBIO Ibio Inc. | 0.22% | 415,606 | $1.0M | Reduce -12.7% |
| ITOS Iteos Therapeutics Inc. | 0.22% | 131,599 | $1.0M | Reduce -65.1% |
| KZR Kezar Life Sciences Inc. | 0.21% | 147,404 | $991K | Reduce -89.0% |
| OABI Omniab Inc. | 0.21% | 278,108 | $985K | Reduce -79.2% |
| REGN Regeneron Pharmaceuticals | 0.21% | 1,361 | $969K | Add +56.3% |
| GPCR Structure Therapeutics Inc. | 0.20% | 35,319 | $958K | New |
| BEAM Beam Therapeutics Inc. | 0.20% | 38,312 | $950K | Reduce -12.7% |
| MLTX Moonlake Immunotherapeutics | 0.20% | 17,424 | $944K | Reduce -25.7% |
| PFE Pfizer Inc. | 0.20% | 35,050 | $930K | Reduce -2.5% |
| FULC Fulcrum Therapeutics Inc. | 0.20% | 196,248 | $922K | Add +251.7% |
| DHR Danaher Corp. | 0.20% | 4,000 | $918K | New |
| DNLI Denali Therapeutics Inc. | 0.19% | 44,826 | $914K | Reduce -56.0% |
| SRRK Scholar Rock Holding Corp. | 0.18% | 19,505 | $843K | Add +62.5% |
| ANSC Agriculture & Natural Soluti | 0.18% | 80,362 | $843K | No change |
| SPRO Spero Therapeutics Inc. | 0.18% | 801,277 | $825K | Add +7.8% |
| KVAUF Keen Vision Acquisition Corp. | 0.18% | 75,000 | $824K | No change |
| ATXS Astria Therapeutics Inc. | 0.17% | 90,984 | $813K | Reduce -2.5% |
| CAPR Capricor Therapeutics Inc. | 0.17% | 56,120 | $774K | Add +130.9% |
| NMRA Neumora Therapeutics Inc. | 0.15% | 68,608 | $727K | New |
| VYGR Voyager Therapeutics Inc. | 0.15% | 126,792 | $719K | Add +212.0% |
| BIOA Bioage Labs Inc. | 0.15% | 123,037 | $712K | New |
| ALEC Alector Inc. | 0.15% | 368,330 | $696K | Reduce -14.1% |
| ALNY Alnylam Pharmaceuticals Inc. | 0.15% | 2,900 | $682K | New |
| INDV Indivior Ltd. | 0.14% | 54,057 | $672K | No change |
| DAWN Day One Biopharmaceuticals I | 0.14% | 53,023 | $672K | Reduce -0.2% |
| CDTX Cidara Therapeutics Inc. | 0.14% | 24,938 | $670K | New |
| KPRX Kiora Pharmaceuticals Inc. | 0.14% | 200,221 | $661K | Add +1.9% |
| TARA Protara Therapeutic Inc. | 0.14% | 122,690 | $648K | New |
| TIL Instil Bio Inc. | 0.13% | 31,708 | $605K | Add +33.8% |
| OGN Organon & Co. | 0.13% | 40,200 | $600K | Add +1196.8% |
| SLDB Solid Biosciences Inc. | 0.13% | 148,903 | $596K | Reduce -87.0% |
| ONC Beone Medicines Ltd.-ADR filed as BEIGENE LTD | 0.12% | 2,974 | $549K | Add +204.1% |
| USFR Wisdomtree Floating Rate Tre | 0.11% | 10,000 | $503K | No change |
| VRDN Viridian Therapeutics Inc. | 0.11% | 26,000 | $498K | Add +182.4% |
Options reported separately and not counted above: PTGX calls ($5.1M), XBI calls ($4.5M), JNJ calls ($1.4M), CAPR calls ($1.3M), CYTK calls ($710K), AKRO calls ($626K), APLT calls ($454K), BMRN calls ($329K), TARS calls ($277K), RGNX calls ($138K), PHAT calls ($82K), CRVS puts ($80K), and 3 more.
Other holdings (14): bonds, preferreds, convertibles and warrants · $15.9M (not counted above)
| Security | Class | Shares / Principal | Value | Change |
|---|---|---|---|---|
| COHERUS ONCOLOGY INC (CHRS 1.5 04/15/26) | NOTE 1.500% 4/1 · principal | 5,625,000 | $5.5M | New |
| GOSSAMER BIO INC (GOSS 5 06/01/27) | NOTE 5.000% 6/0 · principal | 8,000,000 | $4.4M | New |
| BRIDGEBIO PHARMA INC (BBIO 2.25 02/01/29) | NOTE 2.250% 2/0 · principal | 4,500,000 | $3.9M | New |
| BRIDGEBIO PHARMA INC (BBIO 2.5 03/15/27) | NOTE 2.500% 3/1 · principal | 2,000,000 | $2.1M | New |
| AAM.WS Aa Mission Acquisition -30 | *W EXP 08/01/203 | 505,099 | $35K | No change |
| GLSTR Global Star Acquisition-RTS | RIGHT 99/99/9999 | 88,560 | $13K | No change |
| JVSAR Jvspac Acquisition Corp.-RTS | RIGHT 11/26/2026 | 30,000 | $9K | No change |
| IROHR Iron Horse Acquisitions Righ | RIGHT 99/99/9999 | 25,000 | $7K | No change |
| GLSTW Global Star Acquisition-27 A | *W EXP 07/15/202 | 120,000 | $4K | No change |
| EMCRF Embrace Change Acq-Rights | RIGHT 10/25/2026 | 13,144 | $1K | No change |
| UCFIW Iron Horse Acquisition Co.-29 | *W EXP 09/30/203 | 25,000 | $875 | No change |
| FTIIW Futuretech II Acq -CW27 | *W EXP 08/18/202 | 30,000 | $462 | No change |
| EMCWF Embrace Change Acquisitio-26 | *W EXP 10/25/202 | 18,000 | $241 | No change |
| AIMWF Aimfinity Investment-CW27 | *W EXP 99/99/999 | 18,000 | $126 | No change |
Total filed on the 13F, all lines: $485.2M.
Portfolio Sells Q3 2024 → Q4 2024
| RPRX Royalty Pharma PLC Class A | Reduce -95.4% | 0.27% | −4.93 |
| KROS Keros Therapeutics Inc. | Reduce -94.8% | 0.08% | −4.25 |
| CYTK Cytokinetics Inc. | Reduce -54.5% | 4.15% | −3.91 |
| BBIO Bridgebio Pharma Inc. | Reduce -53.1% | 3.97% | −2.21 |
| ASND Ascendis Pharma A/S | Reduce -55.8% | 2.09% | −1.95 |
| ZURA Zura Bio Ltd. | Reduce -44.9% | 1.11% | −1.46 |
| IMVT Immunovant Inc. | Reduce -30.4% | 4.16% | −1.25 |
| SLDB Solid Biosciences Inc. | Reduce -87.0% | 0.13% | −1.21 |
| SNDX Syndax Pharmaceuticals Inc. | Sold out | 0.00% | −1.13 |
| KNSA Kiniksa Pharmaceuticals Inte | Reduce -61.9% | 0.70% | −1.13 |
| ANAB Anaptysbio Inc. | Reduce -85.8% | 0.08% | −1.01 |
| BIIB Biogen Inc. | Reduce -89.7% | 0.10% | −0.86 |
| OABI Omniab Inc. | Reduce -79.2% | 0.21% | −0.74 |
| RGNX Regenxbio Inc. | Reduce -70.1% | 0.28% | −0.72 |
| ABSI Absci Corp. | Reduce -84.3% | 0.09% | −0.56 |
| MRUS Merus NV | Reduce -46.9% | 0.73% | −0.55 |
| AAM Aa Mission Acquisition Cor-A | Reduce -44.5% | 1.21% | −0.49 |
| QTTB Q32 Bio Inc. | Sold out | 0.00% | −0.48 |
| DNTH Dianthus Therapeutics Inc. | Reduce -85.1% | 0.08% | −0.46 |
| ITOS Iteos Therapeutics Inc. | Reduce -65.1% | 0.22% | −0.43 |
| PIERIS PHARMACEUTICALS INC | Sold out | 0.00% | −0.40 |
| CLRB Cellectar Biosciences Inc. | Reduce -42.7% | 0.04% | −0.33 |
| DNLI Denali Therapeutics Inc. | Reduce -56.0% | 0.19% | −0.30 |
| VIR Vir Biotechnology Inc. | Reduce -79.9% | 0.10% | −0.30 |
| ALKS Alkermes PLC | Reduce -86.3% | 0.06% | −0.29 |
| ABUS Arbutus Biopharma Corp. | Reduce -25.6% | 1.08% | −0.27 |
| BNTX Biontech SE-ADR | Sold out | 0.00% | −0.20 |
| NVNO Envveno Medical Corporation | Sold out | 0.00% | −0.20 |
| PCVX Vaxcyte Inc. | Sold out | 0.00% | −0.19 |
| ALEC Alector Inc. | Reduce -14.1% | 0.15% | −0.19 |
| NUVL Nuvalent Inc. Class A | Sold out | 0.00% | −0.18 |
| CRNX Crinetics Pharmaceuticals Inc. | Reduce -39.9% | 0.58% | −0.18 |
| AVDL Avadel Pharmaceuticals Ltd. | Sold out | 0.00% | −0.18 |
| BCAX Bicara Therapeutics Inc. | Sold out | 0.00% | −0.17 |
| GERN Geron Corp. | Reduce -39.4% | 0.25% | −0.17 |
| APGE Apogee Therapeutics Inc. | Reduce -27.8% | 0.40% | −0.16 |
| ITCI Intra-Cellular Therapies Inc. | Sold out | 0.00% | −0.16 |
| AGIO Agios Pharmaceuticals Inc. | Sold out | 0.00% | −0.16 |
| RVNC Revance Therapeutics Inc. | Sold out | 0.00% | −0.16 |
| MIRM Mirum Pharmaceuticals Inc. | Sold out | 0.00% | −0.16 |
| MCK McKesson Corp. | Sold out | 0.00% | −0.15 |
| CGEM Cullinan Therapeutics Inc. | Sold out | 0.00% | −0.15 |
| CTMX Cytomx Therapeutics Inc. | Reduce -84.0% | 0.03% | −0.15 |
| TARS Tarsus Pharmaceuticals Inc. | Sold out | 0.00% | −0.14 |
| AGR Avangrid Inc. | Sold out | 0.00% | −0.14 |
| IRON Disc Medicine Inc. | Reduce -81.4% | 0.06% | −0.13 |
| CLYM Climb Bio Inc. | Reduce -70.6% | 0.02% | −0.12 |
| AMLX Amylyx Pharmaceuticals Inc. | Sold out | 0.00% | −0.12 |
| PWSC Powerschool Holdings Inc. Class A | Sold out | 0.00% | −0.11 |
| EXAS Exact Sciences Corp. | Reduce -67.1% | 0.06% | −0.11 |
Portfolio Buys Q3 2024 → Q4 2024
| ZLAB Zai Lab Ltd.-ADR | Add +96.4% | 5.84% | +3.68 |
| IKT Inhibikase Therapeutics Inc. | New | 3.53% | +3.53 |
| ROIV Roivant Sciences Ltd. | Add +16.0% | 8.84% | +2.99 |
| BIL SS SPDR BB 1-3M T-Bill ETF | Add +504.9% | 2.57% | +2.23 |
| BOXX Alpha Architect 1-3 MNTH Box | Add +0.6% | 7.65% | +1.74 |
| ABVX Abivax SA-ADR | Add +190.1% | 2.36% | +1.35 |
| AVR Anteris Technologies Global | New | 1.25% | +1.25 |
| RVMD Revolution Medicines Inc. | Add +283.3% | 1.58% | +1.25 |
| OACCU Oaktree Acquisition III Life | New | 1.08% | +1.08 |
| SNY Sanofi-ADR | New | 1.02% | +1.02 |
| PTGX Protagonist Therapeutics Inc. | Add +4.0% | 8.39% | +0.99 |
| SRPT Sarepta Therapeutics Inc. | Add +463.4% | 1.04% | +0.89 |
| ETNB 89BIO Inc. | Add +7752.7% | 0.86% | +0.85 |
| EDR Endeavor Group Hold Class A | Add +71.6% | 1.40% | +0.82 |
| MLYS Mineralys Therapeutics Inc. | Add +15.4% | 2.21% | +0.73 |
| MNPR Monopar Therapeutics Inc. | New | 0.61% | +0.61 |
| RCKT Rocket Pharmaceuticals Inc. | Add +4816.3% | 0.57% | +0.55 |
| CNTA Centessa Pharmaceuticals Ltd. | Add +561.0% | 0.55% | +0.49 |
| AEROVATE THERAPEUTICS INC | Add +720.7% | 0.52% | +0.48 |
| ASPCU A Spac III Acquisition Corp. | New | 0.46% | +0.46 |
| ALDX Aldeyra Therapeutics Inc. | Add +114.4% | 0.69% | +0.42 |
| CGON CG Oncology Inc. | Add +50.8% | 1.32% | +0.41 |
| RAPT THERAPEUTICS INC | Add +15557.5% | 0.40% | +0.39 |
| PVLA Palvella Therapeutics Inc. | New | 0.37% | +0.37 |
| RYTM Rhythm Pharmaceuticals Inc. | New | 0.37% | +0.37 |
| TEVA Teva Pharmaceutical-SP ADR | Add +35.6% | 0.69% | +0.36 |
| AXSM Axsome Therapeutics Inc. | Add +3176.8% | 0.35% | +0.35 |
| PTCT PTC Therapeutics Inc. | Add +140.1% | 0.46% | +0.34 |
| DCTH Delcath Systems Inc. | Add +381.1% | 0.38% | +0.34 |
| CDMO Avid Bioservices Inc. | New | 0.32% | +0.32 |
| INSM Insmed Inc. | Add +504.7% | 0.32% | +0.28 |
| PSTX Poseida Therapeutics Inc. | New | 0.27% | +0.27 |
| SLNO Soleno Therapeutics Inc. | Add +268.3% | 0.35% | +0.27 |
| JANX Janux Therapeutics Inc. | Add +142.4% | 0.36% | +0.26 |
| ACOG Alpha Cognition Inc. | New | 0.26% | +0.26 |
| SLRN Acelyrin Inc. | Add +731.7% | 0.30% | +0.25 |
| VRNA Verona Pharma Ltd. | Add +191.0% | 0.29% | +0.24 |
| XENE Xenon Pharmaceuticals Inc. | Add +81.2% | 0.42% | +0.24 |
| CTNM Contineum Therapeutics Inc. Class A | Add +817.1% | 0.26% | +0.23 |
| GPCR Structure Therapeutics Inc. | New | 0.20% | +0.20 |
| DHR Danaher Corp. | New | 0.20% | +0.20 |
| KRRO Korro Bio Inc. | Add +17.2% | 0.47% | +0.19 |
| SRRK Scholar Rock Holding Corp. | Add +62.5% | 0.18% | +0.16 |
| FULC Fulcrum Therapeutics Inc. | Add +251.7% | 0.20% | +0.16 |
| NMRA Neumora Therapeutics Inc. | New | 0.15% | +0.15 |
| BIOA Bioage Labs Inc. | New | 0.15% | +0.15 |
| LXEO Lexeo Therapeutics Inc. | Add +196.5% | 0.24% | +0.15 |
| ALNY Alnylam Pharmaceuticals Inc. | New | 0.15% | +0.15 |
| CDTX Cidara Therapeutics Inc. | New | 0.14% | +0.14 |
| TARA Protara Therapeutic Inc. | New | 0.14% | +0.14 |
Options Activity Q3 2024 → Q4 2024
| PTGX Protagonist Therapeutics Inc. | call | New | 132,000 | $5.1M |
| XBI SS SPDR S&P Biotech ETF | call | New | 50,000 | $4.5M |
| XBI SS SPDR S&P Biotech ETF | put | Sold out | 40,000 | $4.0Mbefore exit |
| NVO Novo-Nordisk A/S-Spons ADR | put | Sold out | 20,000 | $2.4Mbefore exit |
| SNDX Syndax Pharmaceuticals Inc. | call | Sold out | 105,000 | $2.0Mbefore exit |
| MCK McKesson Corp. | call | Sold out | 3,000 | $1.5Mbefore exit |
| JNJ Johnson & Johnson | call | New | 10,000 | $1.4M |
| CAPR Capricor Therapeutics Inc. | call | New | 95,000 | $1.3M |
| NVO Novo-Nordisk A/S-Spons ADR | call | Sold out | 10,000 | $1.2Mbefore exit |
| APLT Applied Therapeutics Inc. | call | Add +0.0% | 530,324 | $454K |
| IMVT Immunovant Inc. | call | Sold out | 10,200 | $291Kbefore exit |
| GALT Galectin Therapeutics Inc. | put | Sold out | 55,300 | $152Kbefore exit |
| PHAT Phathom Pharmaceuticals Inc. | call | New | 10,100 | $82K |
| CRVS Corvus Pharmaceuticals Inc. | put | New | 15,000 | $80K |
| SAGE Sage Therapeutics Inc. | call | Sold out | 9,500 | $69Kbefore exit |
| FULC Fulcrum Therapeutics Inc. | call | Sold out | 15,000 | $54Kbefore exit |
| CRVS Corvus Pharmaceuticals Inc. | call | New | 10,000 | $54K |
| TGTX TG Therapeutics Inc. | put | Sold out | 1,000 | $23Kbefore exit |
| GOSS Gossamer Bio Inc. | call | Reduce -0.5% | 19,898 | $18K |
| KROS Keros Therapeutics Inc. | call | Sold out | 300 | $17Kbefore exit |
| ANRO Alto Neuroscience Inc. | put | Sold out | 100 | $1Kbefore exit |
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
Notes & Other Activity Q3 2024 → Q4 2024
| COHERUS ONCOLOGY INC (CHRS 1.5 04/15/26) | NOTE 1.500% 4/1 · principal | New | 5,625,000 | $5.5M |
| GOSSAMER BIO INC (GOSS 5 06/01/27) | NOTE 5.000% 6/0 · principal | New | 8,000,000 | $4.4M |
| BRIDGEBIO PHARMA INC (BBIO 2.25 02/01/29) | NOTE 2.250% 2/0 · principal | New | 4,500,000 | $3.9M |
| BRIDGEBIO PHARMA INC (BBIO 2.5 03/15/27) | NOTE 2.500% 3/1 · principal | New | 2,000,000 | $2.1M |
| TMTCR TMT Acquisition Corp.-RT | RIGHT 03/27/2028 | Sold out | 37,100 | $10Kbefore exit |
| BKHAR Black Hawk Acquisition C-RTS | RIGHT 06/20/2025 | Sold out | 3,000 | $3Kbefore exit |
| AITRR AI Transportation Acquis-RTS | RIGHT 09/01/2028 | Sold out | 7,500 | $1Kbefore exit |
| MKDWW MKD Tech Inc. -29 | *W EXP 06/10/202 | Sold out | 3,270 | $60before exit |
Bonds, preferreds, convertibles and warrants; not part of the stock holdings or percentages above.
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 260 | $2.1B | ABVX, PTGX, ROIV, SPY, IMVT |
| Q1 2026 | 290 | $1.6B | ABVX, PTGX, ROIV, IMVT, SPY |
| Q4 2025Amended | 248 | $1.3B | ABVX, PTGX, ROIV, IMVT, RNAM |
| Q3 2025 | 196 | $1.0B | ABVX, KROS, PTGX, ROIV, BOXX |
| Q2 2025 | 192 | $609.1M | KROS, PTGX, BOXX, ZLAB, ABVX |
| Q1 2025 | 185 | $505.1M | PTGX, BOXX, ROIV, ZLAB, IMVT |
| Q4 2024 | 185 | $469.3M | ROIV, PTGX, BOXX, ZLAB, IMVT |
| Q3 2024 | 244 | $596.5M | CYTK, PTGX, BBIO, BOXX, ROIV |
| Q2 2024 | 231 | $496.6M | PTGX, CYTK, ROIV, BOXX, BBIO |
| Q1 2024 | 223 | $366.2M | BOXX, ROIV, ALNY, PTGX, CYTK |